查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1827439

肾癌药物市场（按癌症类型、治疗类型、给药途径、剂型和最终用户划分）－全球预测，2025-2032

Kidney Cancer Drugs Market by Cancer Type, Treatment Type, Route Of Administration, Dosage Form, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，肾癌药物市场将成长 99 亿美元，复合年增长率为 6.15%。

主要市场统计数据
基准年2024年 61.4亿美元
预计2025年 65.1亿美元
预测年份：2032年 99亿美元
复合年增长率（%） 6.15%

重点概况肾癌药物前景、科学进展、临床实践的转变以及对相关人员的策略影响

在生物学突破、临床实践改进和支付方动态变化的推动下，肾癌治疗领域正经历科学、临床和商业性的快速发展。免疫肿瘤学和分子标靶治疗方法的进展正在重塑治疗模式，催生出新的治疗方法组合和定序策略，这些策略需要临床医生、支付者和产业策略专家的仔细考虑。同时，以患者为中心的考量因素，例如耐受性、给药便利性和生活质量，正日益影响治疗方法的选择和研发重点。

在相关人员应对这一复杂环境的过程中，监管决策、真实世界证据生成和商业性化途径之间的相互作用至关重要。监管机构正在调整核准框架，以适应新的作用机制和加速途径，而临床医生和多学科护理团队则正在将不断发展的证据融入实践中。因此，产业相关人员必须在科学创新与务实的商业化策略之间取得平衡，以应对真实世界的治疗模式和系统层面的限制。因此，从药物发现到永续应用的转变需要跨部门的合作和远见。

最后，引言部分概述了变革的关键驱动因素、再形成医疗保健的新兴治疗层级，以及决定未来几年竞争优势的策略要点，为深入分析奠定了基础。旨在为读者提供一些具有重要意义的主题，供其在评估研发管线优先事项、合作机会和病患可及性策略时重点关注。

精准医疗、免疫肿瘤学的进步以及真实世界证据的整合如何重塑治疗方法选择和商业化策略

随着精准医疗、免疫肿瘤学的进步以及联合治疗的融合，肾癌治疗格局正在发生变革，并重新定义治疗标准。新型标靶治疗日益受到分子谱分析的影响，正在推动从「一刀切」的治疗方法转向以生物标记主导的干预措施，从而最大限度地提高疗效并降低毒性。同时，包括查核点抑制和新型免疫调变器在内的日趋成熟的免疫治疗策略正在扩大患者亚群的持久缓解范围，并促使新的临床试验探索协同组合。

此外，给药途径和便利性也在推动改变。口服标靶药物和其他给药策略正在影响患者的依从性和治疗部位的考量。在临床创新的同时，法律规范和报销途径也在不断调整，以适应具有复杂获益-风险特征的治疗方法，从而影响申办方的开发策略和核准后证据的生成。此外，真实世界数据和患者报告结果在证明价值和指导指南更新方面发挥着越来越重要的作用。

这种转变透过组合科学、伴随诊断和有针对性的真实世界结果专案创造了差异化的机会。行业领导者迫切需要将科学发展与切合实际的可及性计划相结合，投资于能够引起付款人和临床医生共鸣的证据生成，并做好组织能力的准备，以支持日益个性化的治疗模式。

评估近期关税变更对营运和准入的实际影响，并透过灵活的製造和筹资策略减轻影响

国家层级的政策变化可能对医药供应链、定价策略和市场进入产生连锁影响，而近期的关税变化也为医药采购、生产和分销的相关人员带来了新的复杂性。跨境贸易成本会影响筹资策略和策略采购决策，迫使製造商重新评估其生产布局、在地采购选择和库存策略，以维持持续供应和竞争性经济效益。

因此，拥有一体化製造地和多元化供应商的企业更有能力吸收关税带来的成本压力，而规模较小的企业则可能面临更大的营运负担。此外，管理复杂生物製药和小分子疗法的医疗系统和专科药房可能需要调整其合约惯例和库存管理，以保持医疗服务的可负担性和连续性。从策略角度来看，医疗保健机构应优先考虑供应链视觉性、情境规划和付款人对话，以管理产品成本上涨间接导致的报销影响。

展望未来，商业、法律和营运团队之间的协调规划对于缓解关税相关的干扰至关重要。透过近岸外包、双重采购和灵活製造来强调韧性可以降低风险，而与相关人员的透明沟通有助于维护临床医生和患者的信心。最终，将关税考量纳入策略规划可以降低执行风险，并支持永续获得基本治疗方法。

基于细分的详细见解表明，癌症亚型、治疗方式、给药途径、剂型和治疗环境将决定临床开发和商业化路径

细分洞察表明，治疗药物的开发和商业化策略必须根据不同癌症类型、治疗方式、给药途径、剂型和最终用户的临床和给药特征进行量身定制。根据癌症类型，肾细胞癌、肾肉瘤、移行细胞癌和肾母细胞威尔姆氏肿瘤的治疗方案和临床试验设计存在显着差异，每种适应症都呈现出独特的生物学驱动因素、患者人口统计和临床终点，这些都会影响监管策略和临床应用途径。因此，申办方应制定与每种癌症亚型的自然病程和未满足需求相符的证据产生计画。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 下一代 HIF-2a 抑制剂在晚期肾细胞癌的开发和临床试验成功
  • 人工智慧驱动的生物标记在肾癌个人化治疗策略中的整合度不断提高
  • 扩大免疫疗法和标靶治疗联合治疗显示出更高的生存率
  • 针对转移性肾细胞癌中碳酸酐酶IX的新兴抗体药物复合体
  • 透过优化多激酶抑制剂来克服抗药性机制的关注度不断提高
  • 核准的降低高风险局部肾癌復发风险的辅助性治疗的进展
  • VEGF抑制剂生物相似药的快速发展推动了市场竞争并降低了成本
  • 加大尿液液态生物检体诊断的投资，用于监测治疗后的微量残存疾病

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第八章肾癌药物市场（依癌症类型）

  • 肾臟细胞癌
  • 肾臟肉瘤
  • 移行细胞癌
  • 威尔姆氏肿瘤

第九章肾癌药物市场（依治疗类型）

  • 化疗
  • 荷尔蒙疗法
  • 免疫疗法
    • 查核点抑制剂
      • 细胞激素
      • PD-1抑制剂
  • 新治疗方法
  • 标靶治疗

第 10 章肾癌药物市场（依给药途径）

  • 静脉
  • 口服

第11章 肾癌药物市场（以剂型）

  • 胶囊
  • 注射
  • 药片

第 12 章肾癌药物市场（依最终使用者）

  • 门诊手术中心
  • 医院
  • 专科诊所

第十三章肾癌药物市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章肾癌药物市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 15 章。按国家/地区分類的肾癌药物市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Merck & Co., Inc.
    • Bristol-Myers Squibb Company
    • Pfizer Inc.
    • Novartis AG
    • Roche Holding AG
    • AstraZeneca PLC
    • Exelixis, Inc.
    • Bayer AG
    • Ipsen SA
    • Eisai Co., Ltd.
Product Code: MRR-434CCDA0527F

The Kidney Cancer Drugs Market is projected to grow by USD 9.90 billion at a CAGR of 6.15% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 6.14 billion
Estimated Year [2025] USD 6.51 billion
Forecast Year [2032] USD 9.90 billion
CAGR (%) 6.15%

A focused overview of the kidney cancer therapeutics landscape that frames scientific advances, clinical practice shifts, and strategic implications for stakeholders

The kidney cancer therapeutics landscape has entered a period of rapid scientific, clinical, and commercial evolution driven by breakthroughs in biology, refinements in clinical practice, and shifting payer dynamics. Advances in immuno-oncology and targeted agents have reframed treatment paradigms, creating new therapeutic combinations and sequencing strategies that demand careful scrutiny from clinicians, payers, and industry strategists. At the same time, patient-centric considerations such as tolerability, administration convenience, and quality of life are increasingly influencing therapeutic choice and development priorities.

As stakeholders navigate this complex environment, the interplay between regulatory decisions, real-world evidence generation, and commercial access pathways becomes critical. Regulatory authorities are adapting approval frameworks to accommodate novel mechanisms of action and accelerated pathways, while clinicians and multidisciplinary care teams are integrating evolving evidence into practice. Consequently, industry players must balance scientific innovation with pragmatic commercialization tactics that address real-world treatment patterns and system-level constraints. Transitioning from discovery to sustainable adoption therefore requires cross-functional alignment and foresight.

Ultimately, the introduction establishes a foundation for deeper analysis by outlining the primary drivers of change, the emerging therapeutic classes reshaping care, and the strategic imperatives that will define competitive advantage over the coming years. The intent is to orient readers toward the high-impact themes that warrant focused attention when assessing pipeline prioritization, partnership opportunities, and patient-access strategies.

How precision medicine, immuno-oncology progress, and real-world evidence integration are collectively reshaping therapeutic choices and commercialization strategies

The therapeutic landscape for kidney cancer is undergoing transformative shifts as precision medicine, immuno-oncology advances, and combination regimens converge to redefine standards of care. Emerging targeted therapies are increasingly informed by molecular profiling, prompting a move away from one-size-fits-all approaches toward biomarker-driven interventions that seek to maximize efficacy while mitigating toxicity. Concurrently, the maturation of immunotherapeutic strategies, including checkpoint inhibition and novel immune modulators, is expanding the range of durable responses for subsets of patients and prompting new trials that explore synergistic combinations.

In addition, the route and convenience of administration are catalyzing change; oral targeted agents and alternative dosing strategies are influencing patient adherence and site-of-care considerations. Parallel to clinical innovations, regulatory frameworks and reimbursement pathways are adapting to accommodate therapies with complex benefit-risk profiles, which in turn influences sponsor development strategies and post-approval evidence generation. Moreover, real-world data and patient-reported outcomes are playing an expanded role in demonstrating value and informing guideline updates.

These shifts collectively create opportunities for differentiation through combination science, companion diagnostics, and targeted real-world outcomes programs. For industry leaders, the imperative is to align scientific development with pragmatic access planning, invest in evidence-generation that resonates with payers and clinicians, and prepare organizational capabilities to support increasingly personalized treatment paradigms.

Assessing the practical operational and access ramifications of recent tariff shifts and how resilient manufacturing and procurement strategies can mitigate disruption

Policy changes at the national level can have cascading effects across pharmaceutical supply chains, pricing strategies, and market access efforts, and recent tariff dynamics have added a new layer of complexity for stakeholders involved in drug sourcing, manufacturing, and distribution. Cross-border trade costs have the potential to influence procurement strategies and strategic sourcing decisions, prompting manufacturers to reassess manufacturing footprints, local sourcing options, and inventory strategies to maintain uninterrupted supply and competitive economics.

As a result, companies with integrated manufacturing and diversified supplier bases are better positioned to absorb tariff-driven cost pressures, while smaller players may face heightened operational strain. In addition, health systems and specialty pharmacies that manage complex biologic and small-molecule therapeutics may need to adapt contracting practices and inventory management to preserve affordability and continuity of care. From a strategic perspective, organizations should prioritize supply chain visibility, scenario planning, and dialogue with payers to manage reimbursement impacts that arise indirectly from increased product costs.

Moving forward, coordinated planning across commercial, legal, and operations teams will be critical to mitigate tariff-related disruptions. Emphasizing resilience through nearshoring, dual sourcing, and flexible manufacturing can reduce exposure, while transparent stakeholder communication helps to preserve trust among clinicians and patients. Ultimately, integrating tariff considerations into strategic planning reduces execution risk and supports sustainable access to essential therapies.

Detailed segmentation-led insight showing how cancer subtype, treatment modality, route, dosage form, and care setting determine clinical development and commercialization pathways

Segmentation insights reveal that therapeutic development and commercialization strategies must be tailored to the distinct clinical and delivery characteristics of each cancer type, treatment modality, route of administration, dosage form, and end user. Based on Cancer Type, therapeutic programs and clinical trial designs differ markedly across Renal Cell Carcinoma, Renal Sarcoma, Transitional Cell Carcinoma, and Wilms Tumor, with each indication presenting unique biological drivers, patient demographics, and clinical endpoints that influence regulatory strategy and clinical adoption pathways. Consequently, sponsors should design evidence-generation plans that align with the natural history and unmet needs of each cancer subtype.

Based on Treatment Type, differentiation hinges on modality-specific considerations. Chemotherapy and hormone therapy retain roles in specific contexts, while immunotherapy and targeted therapy are increasingly central to treatment algorithms. Within immunotherapy, Checkpoint Inhibitors represent a pivotal class, and these agents further diverge into subcategories such as Cytokines and PD-1 Inhibitors, each carrying distinct mechanisms, toxicity profiles, and monitoring needs. Novel therapies, including cell-based and precision targeted constructs, introduce additional complexity in manufacturing and delivery that must be addressed early in development planning.

Based on Route Of Administration, the distinction between Intravenous and Oral delivery drives patient preference, site-of-care economics, and adherence considerations. Oral agents can shift therapy from infusion centers to outpatient management, altering payer mix and convenience for patients, whereas intravenous therapies may require infrastructure and resourcing at infusion sites. Based on Dosage Form, formulation decisions between Capsule, Injection, and Tablet affect pharmacokinetics, patient experience, and cold chain requirements. Finally, based on End User, differences among Ambulatory Surgical Centers, Hospitals, and Specialty Clinics shape contracting, reimbursement, and logistics. Integrating these segmentation dimensions into product development and commercial planning enables more precise targeting of clinical programs, reimbursement strategies, and provider engagement efforts.

How regional regulatory variance, payer expectations, and clinical infrastructure across the Americas, Europe Middle East & Africa, and Asia-Pacific influence access and commercialization

Regional dynamics materially influence clinical trial enrollment, regulatory approaches, pricing expectations, and patterns of care, and a nuanced understanding of geographic variation is essential for global strategy. In the Americas, diverse payer models and a strong emphasis on innovation influence adoption trajectories for novel therapies, while real-world evidence generated in this region often informs payer decisions and guideline updates. Moreover, the concentration of leading academic centers supports early-phase trial activity, facilitating rapid evaluation of promising combinations and biomarkers.

In Europe, Middle East & Africa, heterogeneous regulatory environments and variations in reimbursement approaches require tailored access plans that reflect national-level health technology assessment processes and budgetary constraints. Stakeholders operating across these regions must align dossier development and health economic modelling with local evidentiary needs to navigate reimbursement pathways successfully. Transitioning eastward, the Asia-Pacific region spans mature health systems alongside emerging markets, each with distinct expectations regarding clinical evidence, pricing, and local manufacturing. Governments and private payers in this region are increasingly investing in oncology infrastructure and biomarker testing capacity, which in turn shapes demand for targeted therapies.

Taken together, regional strategies should be informed by local clinical practice patterns, regulatory timelines, and payer evidence requirements. Cross-border initiatives that leverage local partnerships, foster capacity building, and adapt commercial models to national contexts can accelerate access and optimize patient outcomes while respecting the unique operational realities of each geography.

Company strategic postures and partnership models that accelerate development, global reach, and access for innovative kidney cancer therapies

Company-level dynamics reflect diverse strategic postures ranging from focused biologics specialists to diversified pharmaceutical organisations pursuing integrated oncology portfolios. Leading developers tend to concentrate investments in combination science, biomarker-driven indications, and real-world outcomes programs designed to demonstrate durable clinical benefit and cost-effectiveness to payers. At the same time, midsized and emerging companies frequently pursue niche indications or innovative delivery platforms to carve differentiated value propositions and attract strategic partnerships or licensing opportunities.

In addition, the competitive environment incentivizes collaboration across the ecosystem: alliances between biotech innovators and established commercial organisations can accelerate late-stage development and expand global reach. Manufacturing partnerships and contract development collaborations are likewise crucial for managing the complex supply chains associated with biologics and cell therapies. Moreover, companies that invest early in post-approval evidence generation, patient support programs, and streamlined access solutions tend to enable smoother adoption of new therapies in diverse care settings.

Strategically, management teams should prioritize integrated planning that aligns clinical development, regulatory engagement, and market access activities. This approach reduces time-to-adoption risk, positions products competitively in crowded treatment landscapes, and enhances the potential for sustainable patient access across heterogeneous healthcare systems.

Practical strategic actions industry leaders should take to align biomarker development, evidence generation, supply resilience, and commercial execution for durable impact

Industry leaders should adopt a multi-dimensional playbook that aligns scientific priorities with pragmatic commercialization and access tactics, enabling rapid translation of promising therapies into sustainable clinical use. First, executives must prioritize biomarker-driven development and invest in companion diagnostics to ensure patient selection strategies are robust and clinically actionable. This alignment reduces development risk and strengthens the evidentiary case for reimbursement by demonstrating targeted benefit in defined patient subsets.

Second, organizations should proactively design post-approval evidence programs and real-world outcome studies that address payer and clinician questions about durability, safety in broader populations, and comparative effectiveness. These programs should be integrated with health economic models to support pricing and reimbursement dialogues. Third, resilience in supply chain and sourcing should be established through diversification, strategic partnerships, and contingency planning to mitigate the operational impact of external cost pressures. Fourth, companies must adapt commercial models to accommodate shifts in route of administration and care setting, ensuring that patient support services, specialty pharmacy strategies, and provider education programs are coordinated to facilitate uptake.

Finally, leaders should pursue collaborative models with academic centers, payers, and patient advocacy groups to co-create evidence, enhance trial enrollment, and align on value frameworks. By executing this set of actions, organizations can accelerate adoption while maintaining focus on patient outcomes and payer-relevant value propositions.

An evidence-driven research methodology combining literature synthesis, expert consultations, real-world data review, and scenario-based analytical rigor to validate insights

The research underpinning this report combined a multi-source evidence framework with rigorous analysis to ensure comprehensive, reproducible findings. Primary data inputs included systematic reviews of peer-reviewed clinical literature, regulatory decisions, and guidance documents, supplemented by an examination of real-world evidence sources and practice-pattern analyses. These elements were synthesized to map therapeutic evolution, clinical adoption trends, and the operational implications for development and commercialization.

In parallel, expert consultations with oncologists, health economists, reimbursement specialists, and supply chain professionals informed interpretation and contextualization of findings. These engagements helped validate assumptions about clinical practice, unmet needs, and payer considerations, and they guided prioritization of strategic recommendations. Analytical approaches incorporated qualitative synthesis of clinical and policy trends alongside scenario-based assessments of operational risks, ensuring that conclusions remain robust across plausible market conditions.

Finally, the methodology emphasized transparency and reproducibility: data sources and analytical frameworks were documented to enable stakeholders to trace insights back to original evidence streams. This structured approach supports confident decision-making and facilitates targeted follow-up analyses tailored to specific organizational questions.

Concluding synthesis emphasizing the need to combine innovative science with disciplined commercialization and regional strategies to improve patient outcomes

In conclusion, the kidney cancer therapeutics environment is characterized by rapid innovation, shifting care paradigms, and increasing emphasis on evidence that demonstrates meaningful clinical and economic value. Progress in targeted therapies and immuno-oncology has expanded therapeutic options across multiple renal cancer types, while evolving delivery formats and site-of-care dynamics continue to influence adoption. At the same time, operational considerations such as supply chain resilience and regional regulatory variance are central to enabling access and sustaining therapy continuity.

For stakeholders, the imperative is to integrate scientific ambition with pragmatic commercialization and access planning. This requires early alignment on biomarker strategies, investment in post-approval evidence generation that resonates with payers and clinicians, and proactive supply chain planning to mitigate external cost pressures. Moreover, regional differentiation in regulatory, payer, and clinical practice contexts mandates tailored strategies that reflect local realities while leveraging global capabilities.

Taken together, a balanced strategy that couples innovative science with disciplined execution will position organizations to deliver meaningful improvements in patient outcomes while navigating the complexities of a rapidly transforming therapeutic landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Dev and clinical trial success of next generation HIF-2a inhibitors in advanced renal cell carcinoma
  • 5.2. Growing integration of AI-driven biomarkers for personalized therapeutic strategies in kidney cancer
  • 5.3. Expansion of combination immunotherapy and targeted therapy regimens showing superior survival benefits
  • 5.4. Emergence of novel antibody-drug conjugates targeting carbonic anhydrase IX in metastatic renal cell carcinoma
  • 5.5. Increasing focus on overcoming drug resistance mechanisms through multi-kinase inhibitor optimization
  • 5.6. Advancements in adjuvant therapy approvals reducing recurrence risk in high-risk localized kidney cancer
  • 5.7. Surge in biosimilar development for VEGF inhibitors driving market competition and cost reduction
  • 5.8. Rising investment in urine-based liquid biopsy diagnostics to monitor minimal residual disease post-treatment

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Kidney Cancer Drugs Market, by Cancer Type

  • 8.1. Renal Cell Carcinoma
  • 8.2. Renal Sarcoma
  • 8.3. Transitional Cell Carcinoma
  • 8.4. Wilms Tumor

9. Kidney Cancer Drugs Market, by Treatment Type

  • 9.1. Chemotherapy
  • 9.2. Hormone Therapy
  • 9.3. Immunotherapy
    • 9.3.1. Checkpoint Inhibitors
      • 9.3.1.1. Cytokines
      • 9.3.1.2. PD-1 Inhibitors
  • 9.4. Novel Therapies
  • 9.5. Targeted Therapy

10. Kidney Cancer Drugs Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral

11. Kidney Cancer Drugs Market, by Dosage Form

  • 11.1. Capsule
  • 11.2. Injection
  • 11.3. Tablet

12. Kidney Cancer Drugs Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Kidney Cancer Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Kidney Cancer Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Kidney Cancer Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Merck & Co., Inc.
    • 16.3.2. Bristol-Myers Squibb Company
    • 16.3.3. Pfizer Inc.
    • 16.3.4. Novartis AG
    • 16.3.5. Roche Holding AG
    • 16.3.6. AstraZeneca PLC
    • 16.3.7. Exelixis, Inc.
    • 16.3.8. Bayer AG
    • 16.3.9. Ipsen S.A.
    • 16.3.10. Eisai Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. KIDNEY CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. KIDNEY CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. KIDNEY CANCER DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY RENAL CELL CARCINOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY RENAL CELL CARCINOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY RENAL CELL CARCINOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY RENAL CELL CARCINOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY RENAL SARCOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY RENAL SARCOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY RENAL SARCOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY RENAL SARCOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY RENAL SARCOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY RENAL SARCOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TRANSITIONAL CELL CARCINOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TRANSITIONAL CELL CARCINOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TRANSITIONAL CELL CARCINOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TRANSITIONAL CELL CARCINOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TRANSITIONAL CELL CARCINOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TRANSITIONAL CELL CARCINOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY WILMS TUMOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY WILMS TUMOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY WILMS TUMOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY WILMS TUMOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY WILMS TUMOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY WILMS TUMOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY HORMONE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY HORMONE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY HORMONE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY HORMONE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY HORMONE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY HORMONE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CYTOKINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CYTOKINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CYTOKINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CYTOKINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CYTOKINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY NOVEL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY NOVEL THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY NOVEL THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY NOVEL THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY NOVEL THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY NOVEL THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. LATIN AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. LATIN AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE KIDNEY CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE KIDNEY CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE KIDNEY CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE KIDNEY CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. MIDDLE EAST KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. MIDDLE EAST KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. MIDDLE EAST KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST KIDNEY CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 228. MIDDLE EAST KIDNEY CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST KIDNEY CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 230. MIDDLE EAST KIDNEY CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 232. MIDDLE EAST KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. MIDDLE EAST KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 244. AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 245. AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 246. AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 247. AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 248. AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 249. AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 250. AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 251. AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. ASEAN KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. ASEAN KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. ASEAN KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. ASEAN KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. ASEAN KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. ASEAN KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. ASEAN KIDNEY CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 278. ASEAN KIDNEY CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 279. ASEAN KIDNEY CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 280. ASEAN KIDNEY CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 281. ASEAN KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 282. ASEAN KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 283. ASEAN KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 284. ASEAN KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 285. ASEAN KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. ASEAN KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. GCC KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. GCC KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. GCC KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. GCC KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. GCC KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. GCC KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. GCC KIDNEY CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 294. GCC KIDNEY CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 295. GCC KIDNEY CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 296. GCC KIDNEY CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 297. GCC KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 298. GCC KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 299. GCC KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 300. GCC KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 301. GCC KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 302. GCC KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPEAN UNION KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPEAN UNION KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPEAN UNION KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPEAN UNION KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPEAN UNION KIDNEY CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPEAN UNION KIDNEY CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION KIDNEY CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPEAN UNION KIDNEY CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPEAN UNION KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 314. EUROPEAN UNION KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 315. EUROPEAN UNION KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 316. EUROPEAN UNION KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 317. EUROPEAN UNION KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 318. EUROPEAN UNION KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 319. BRICS KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 320. BRICS KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 321. BRICS KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 322. BRICS KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 323. BRICS KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 324. BRICS KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 325. BRICS KIDNEY CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 326. BRICS KIDNEY CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 327. BRICS KIDNEY CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 328. BRICS KIDNEY CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 329. BRICS KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 330. BRICS KIDNE